Stroke Subtype Differentiation Using GFAP and RBP4 Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating ischemic stroke from hemorrhagic stroke are limited by the availability and reliability of brain imaging technologies in primary hospitals, and existing biomarker-based tests are not sufficiently rapid or accurate for timely treatment initiation.
Innovation Solution
An in vitro method using a combination of glial fibrillary acidic protein (GFAP) and other biomarkers such as neurofilament medium polypeptide (NEF3), β-synuclein, and retinol binding protein 4 (RBP4) to differentiate between ischemic and hemorrhagic strokes, with specific reference values for determining appropriate therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If brain imaging data by CT or MRI is used for stroke subtype diagnosis, then diagnostic accuracy is improved, but availability and accessibility deteriorate due to lack of resources in primary hospitals
Solution Approach 1:
The patent extracts the diagnostic function from complex imaging equipment (CT/MRI) and transfers it to a simple blood test system. By identifying specific biomarkers (GFAP, S100B, RBP4, APOB, LPL) that can be measured in blood samples, the diagnostic capability is extracted from the imaging modality and embodied in a routine laboratory test that is widely available in primary hospitals.
Solution Approach 2:
The patent introduces blood-based biomarkers as an intermediary between the patient's brain condition and the diagnostic result. Instead of directly imaging the brain with expensive equipment, the method uses biomarkers circulating in the blood as mediators that reflect the underlying brain pathology, enabling indirect but accurate diagnosis through accessible blood testing.
2Reliability
If brain imaging by CT or MRI is used for stroke differentiation, then diagnostic reliability is improved, but susceptibility to error increases when medical personnel are inexperienced or inadequately trained
Solution Approach 1:
The patent replaces the mechanical/operational system of image acquisition and interpretation (requiring skilled personnel to operate imaging equipment and analyze complex images) with a biochemical measurement system. The diagnostic process is substituted from visual/image-based interpretation to quantitative biomarker measurement, which can be automatically analyzed by laboratory systems without requiring specialized neurological interpretation skills.
Solution Approach 2:
The patent changes the diagnostic parameter from complex image patterns requiring expert interpretation to specific biochemical concentrations (biomarker levels) that can be objectively measured and compared against established reference ranges. This parameter transformation makes the diagnostic process more standardized and less dependent on individual operator expertise.
3Productivity
If existing biomarker-based tests are used for stroke differentiation, then rapid diagnosis is achieved, but accuracy deteriorates compared to imaging methods
Solution Approach 1:
The patent merges multiple biomarkers (GFAP, S100B, RBP4, APOB, LPL) into a combined diagnostic approach. By measuring several biomarkers simultaneously and integrating their information, the method achieves both the speed of laboratory testing and the accuracy previously requiring imaging. The combination of multiple biomarkers compensates for individual limitations and provides a more robust diagnostic signal.
Data Source
Figure 1
Figure 1
Figure 2
AI summary
The invention relates to a method for differentiating ischemic stroke from hemorrhagic stroke in a patient and to a method for selecting a patient suffering stroke for a therapy with an antithrombotic agent or with an agent capable of reducing blood pressure based on the determination of the level of GFAP in a sample of said patient in combination with one or more markers selected from the group consisting of NEF3, β-synuclein, CARNS1 and RBP4, or based on determining the level of RBP4 in a sample of said patient. Furthermore, the invention relates to a kit comprising a reagent for detecting the level of a marker selected from GFAP NEF3, β-synuclein, CARNS1, RBP4 or a combination thereof and to the use of the said kit in the methods of the invention.